Most Recent
AUSTRAC's long-running investigation into NAB's compliance with anti-money laundering and counter-terrorism financing laws has progressed, with the matter being referred to the financial crime regulator's enforcement team.
Racing NSW CEO Peter V'landys AM is challenging a judge's decision to toss his defamation case against the ABC over a 7:30 segment that revealed racehorses were being killed in violation of industry rules.
The Beatles hit producer EMI has lost its "ambitious" opposition to Australian craft company Spotlight registering 'Abbey Road' as a trade mark for its yarn products.
A judge has extended an injunction barring a former manager of non-bank lender Liberty Financial from working for a unit of Wingate Group until after trial in a case over a restraint clause in the executive's contract.
A Victoria Supreme Court judge weighing for the first time an application by a law firm for a percentage cut of recoveries in class actions has been told to reject the bid because group members would fare better under the firm's current no win, no fee funding arrangement.
Payments provider Tyro is facing two potential class actions over a days-long terminal outage that left many businesses unable to accept payments, the first of which is expected to be filed "imminently".
When Johnson Winter & Slattery’s George Croft is asked what he loves about working for clients in the energy and resources sectors, the tangible nature of the field with its deep rumbling ore crushers and haulage trains kilometres long really brings out his excitement.
Kraft has agreed to pay Bega $9.25 million as part of a settlement resolving a long-running battle over peanut butter trade dress rights, after the US consumer goods giant exhausted all its options for appealing a ruling that found Bega had acquired the rights to the trade dress.
Failed vocational education provider Phoenix Institute has taken three of its former directors to court claiming they breached the Corporations Act in the lead-up to its collapse and should compensate the company.
A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the delayed launch of generic versions of their antipsychotic drug Abilify, but warned there had to be a cut-off point for preparing the decade-long dispute for trial.